1型糖尿病中伴或不伴糖尿病周围神经病变的神经病理性疼痛
本研究在糖尿病干预与并发症流行病学(EDIC)研究中每年使用密歇根神经病变筛查量表(MNSI)评估1324例1型糖尿病参与者(1994-2020年)。第26年时神经病理性疼痛累积发生率为57%,其中伴临床体征者36%、不伴临床体征者46%;患病率20%,提示频繁缓解,且缓解率与止痛药使用无关。除HbA1c外,女性与不伴临床体征的神经病理性疼痛相关。
要点
- 1型糖尿病中神经病理性疼痛累积发生率高,第26年达57%。
- 相当比例神经病理性疼痛不伴MNSI临床体征(46% vs 36%)。
- 疼痛缓解常见,且年化缓解率与止痛药使用无关。
核心结论
- 1型糖尿病中神经病理性疼痛发生率高,且常在不伴MNSI临床神经病变体征时出现。
- 疼痛缓解不能由止痛药使用解释。
- 需要有效的临床策略来识别和管理神经病理性疼痛。
研究设计与样本
- 在EDIC研究中对1324例1型糖尿病参与者每年(1994-2020年)施测密歇根神经病变筛查量表(MNSI)。
- EDIC第1年参与者中位年龄36岁(四分位距30,41),糖尿病病程13年(10,18),HbA1c 7.9%(7.2,8.9)。
- 神经病理性疼痛伴糖尿病周围神经病变临床体征(NP DPN+)定义为自报神经病理性疼痛加检查评分>2;不伴临床体征(NP DPN-)定义为自报神经病理性疼痛加检查评分≤2。
主要发现
- 第26年(中位糖尿病病程39年)神经病理性疼痛累积发生率为57%,伴或不伴临床体征分别为36%(NP DPN+)与46%(NP DPN-)。
- 第26年神经病理性疼痛患病率为20%(NP DPN+ 11%,NP DPN- 9%),提示频繁缓解。
- 年化缓解率与止痛药使用与否相似。
- 除HbA1c外,女性与NP DPN-相关。
关键数值与推荐
- NP DPN+:自报神经病理性疼痛且MNSI检查评分>2。
- NP DPN-:自报神经病理性疼痛且MNSI检查评分≤2。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Diabetic peripheral neuropathy (DPN) is common; however, the features and burden of neuropathic pain (NP) in type 1 diabetes (T1D) are poorly understood. We evaluated the incidence of first occurrence, annual prevalence, remission, and risk factors for NP during long-term follow-up of participants with T1D. RESEARCH DESIGN AND METHODS: The Michigan Neuropathy Screening Instrument (MNSI) was administered annually (1994-2020) for 1,324 participants in the Epidemiology of Diabetes Interventions and Complications (EDIC) study. NP with clinical signs of DPN (NP DPN+) was defined according to self-reported NP plus an examination score >2, while NP without clinical signs of DPN (NP DPN-) was defined according to self-reported NP and an examination score ≤2. RESULTS: At EDIC year 1, median age for participants was 36 years (interquartile range 30, 41), diabetes duration 13 years (10, 18), and HbA1c 7.9% (7.2, 8.9). At year 26 (median diabetes duration 39 years), cumulative incidence of NP was 57%, regardless of concomitant clinical signs of DPN (36% NP DPN+ vs. 46% NP DPN-). NP prevalence was 20% at 26 years (11% NP DPN+ and 9% NP DPN-), suggesting frequent remission. Annualized remission rates were similar regardless of pain medication use. In addition to HbA1c, female sex was associated with NP DPN-. CONCLUSIONS: NP incidence in T1D was high and frequently occurred in the absence of clinical signs of neuropathy, as assessed with the MNSI. Pain remission was not explained by pain medication use. Effective clinical strategies for identification and management are needed.
引用
- Braffett BH, El Ghormli L, Albers JW, et al. Neuropathic Pain With and Without Diabetic Peripheral Neuropathy in Type 1 Diabetes. Diabetes Care. 2024. PMID: 38300889. doi:10.2337/dc23-1749
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。